Statin Impact on Hepatic Decompensation

Tanta University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Quality of Life

Treatments: Drug: Placebo; Drug: Atorvastatin 20mg

Study type: Interventional

Funder types: Other

Identifiers

NCT05563389

Statin and iver cirrhosis

Details and patient eligibility

About

The study aims to evaluate the impact of statin on hepatic decompensation.

Full description

Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Enrollment: 100 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• cirrhosis adult both sex

Exclusion criteria

• renal insufficiency

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

PLACEBO

Placebo Comparator group

Description:

placebo formula

Treatment:

Drug: Placebo

statin

Active Comparator group

Description:

atorvastatin tablets

Treatment:

Drug: Atorvastatin 20mg